SCN5A mutations involving the α-subunit of the cardiac voltage-gated muscle sodium channel (NaV1.5) result in different cardiac channelopathies with an autosomal-dominant inheritance such as Brugada syndrome. On the other hand, mutations in SCN4A encoding the α-subunit of the skeletal voltage-gated sodium channel (NaV1.4) cause non-dystrophic myotonia and/or periodic paralysis. In this study, we investigated whether cardiac arrhythmias or channelopathies such as Brugada syndrome can be part of the clinical phenotype associated with SCN4A variants and whether patients with Brugada syndrome present with nondystrophic myotonia or periodic paralysis and related gene mutations. We therefore screened seven families with different SCN4A variants and non-dystrophic myotonia phenotypes for Brugada syndrome and performed a neurological, neurophysiological and genetic work-up in 107 Brugada families. In the families with an SCN4A-associated non-dystrophic myotonia, three patients had a clinical diagnosis of Brugada syndrome, whereas we found a remarkably high prevalence of myotonic features involving different genes in the families with Brugada syndrome. One Brugada family carried an SCN4A variant that is predicted to probably affect function, one family suffered from a not genetically confirmed non-dystrophic myotonia, one family was diagnosed with myotonic dystrophy (DMPK gene) and one family had a Thomsen disease myotonia congenita (CLCN1 variant that affects function). Our findings and data suggest a possible involvement of SCN4A variants in the pathophysiological mechanism underlying the development of a spontaneous or drug-induced type 1 electrocardiographic pattern and the occurrence of malignant arrhythmias in some patients with Brugada syndrome.
INTRODUCTION
Sodium channel disorders are rare autosomal-dominant inherited diseases. They are caused by mutations in one of the subunit isoforms of voltage-gated sodium channels present in specific tissues such as the skeletal muscle, the cardiac muscle and the nervous system. 1 SCN5A mutations involving the α-subunit of the cardiac voltagegated muscle sodium channel (NaV1.5) result in different cardiac channelopathies with an autosomal-dominant inheritance such as Brugada syndrome (BS). This syndrome is associated with syncope, life-threatening ventricular arrhythmias and sudden cardiac death. In the majority of patients with BS, no gene mutation is identified and only 30% of cases has an SCN5A mutation. 2 The exact prevalence of this orphan disease is unknown, although it has been estimated to affect 1 in 2000 people worldwide. 3 SCN4A encodes the α-subunit of the voltage-gated sodium channel (NaV1.4) in skeletal muscles. Mutations in this gene are responsible for muscular sodium channelopathies, encompassing (non-dystrophic) sodium channel myotonia (SCM), hyperkalemic periodic paralysis (HyperPP), paramyotonia congenita (PMC) and a small percentage of hypokalemic periodic paralysis (HypoPP), as well as congenital myasthenia syndrome. The prevalence of muscular sodium channelopathies in the general population has been estimated to be o1/100 000. 4 Except for nonspecific cardiac arrhythmias described in two SCN4A-associated case reports, 5, 6 no overlapping phenotypes between muscular and cardiac sodium channelopathies have been reported. Based on a personal observation of a patient with a genetically confirmed SCM and BS (patient A1 in Table 1) , we investigated the possible role of SCN4A mutations in the pathophysiology of BS. The possible association between these two rare diseases is supported by several publications, demonstrating the expression of skeletal muscle voltage-gated sodium channels in the cardiac muscle. 5, 7, 8 To determine whether cardiac arrhythmias or channelopathies such as BS can be part of an SCN4A-associated phenotype, we performed a cardiac work-up in the family of this patient as well as in six other families with an SCN4A variant. To increase the power of the tested hypothesis, a second cross-sectional study was conducted to assess the prevalence of muscular sodium channelopathies in BS. Table 3 in Supplementary Material).
MATERIALS AND METHODS

First case/index family
The hypothesis for this study was based on observations compiled from a 64-year-old male (patient A1 in Table 1 ). Electromyography (EMG) findings showed diffuse myotonia without myopathic features, and a short exercise test 11, 12 suggested an SCM. Subsequent SCN4A analysis confirmed the presence of the c.4307T4C variant p.(Leu1436Pro), a variant previously described by Matthews et al. 13 Detailed description of the neurological symptoms of this patient and his family has been published elsewhere. 14 One year earlier, the index was diagnosed with BS ( Figure 1 ) after repeated syncopes and he underwent implantation of a cardioverter defibrillator (ICD). Genetic analysis showed no SCN5A variants that are likely to affect function. However, two polymorphisms (c.1673A4G (p.His558Arg) and c.1141 − 3C4A), described as possible disease-modifying variants, were found. These SCN5A polymorphisms are also present in 20% of the general population. 15, 16 Consecutively, his three daughters (patient A2, A3 and A4) were screened for BS and both polymorphisms, regardless of the presence of the muscular channelopathy.
First study: screening for BS in patients with SCN4A variants Eleven neurologically affected members in six other unrelated families carrying an SCN4A variant (families B to G) underwent a cardiac work-up ( Figure 2 ). Echocardiography demonstrated neither underlying cardiomyopathy nor structural heart disease in any patient. None of the included patients took any antiarrhythmic drugs at inclusion. The SCN4A phenotypes and genotypes of the different families are described in Table 1 . 5, 9, [13] [14] [15] [16] [17] [18] The diagnosis of BS was confirmed if patients had either a spontaneous or a drug-induced ST segment elevation with a type 1 morphology of 42 mm in 41 lead among the right precordial leads (V1-V3). 19 If no spontaneous type I morphology was seen on the electrocardiogram (ECG), a standardized Ajmaline Challenge Test was performed conforming to current guidelines to unmask any concealed forms of BS. 20 In case of established BS, SCN5A genetic analysis was performed, according to the recommendations from the Heart Rhythm Society/European Heart Rhythm Association. 21 SCN5A variant detection in genomic DNA was carried out via high-resolution melting-curve analysis (HRMCA), followed by direct bidirectional Sanger sequencing analysis of aberrant HRMCA melting patterns and of exons and flanking intron regions for which HRMCA was not available. The interpretation was realized through SeqPilot v.4.0.1. using reference transcript NM_198056.2 and NG_008934.1. Other genes associated with BS, accounting for only 5% of all BS, were not screened in the myotonia probands.
Second study: screening for muscular sodium channelopathy in patients with BS One hundred and sixty-nine adult BS patients of 107 Brugada families were recruited between October 2010 and March 2012 from the outpatient clinic of the UZ-Brussel. BS was previously diagnosed in the same manner as in the first study. In addition, a type C BS gene panel analysis of 16 extra BS-associated genes was performed in SCN5A-negative probands who consented for further genome-wide genetic testing. BS gene panel variants were detected via Roche SeqCap v.3 target enrichment (Roche, Vilvoorde, Belgium) and 100 bp pairedend sequencing on an Illumina HiSeq1500 machine (Illumina, Eindhoven, The Netherlands). The in-house developed next-generation sequencing data analysis pipeline uses bwa v.0.7.10-r789, 22 picard-tools v.1.97, 23 Forty-two percent (71/169) of the patients received an ICD based on international recommendations at the time of implant. 26 All patients underwent a clinical and electrophysiological assessment to detect a muscular sodium channelopathy (SCM, PMC, HyperPP and HypoPP) (Figure 2 ). They were interviewed by one of the investigators to assess the presence of episodic weakness and myotonia, the latter by asking about stiffness and pain, as well as alleviating and precipitating factors. All patients were tested for clinical myotonia, including evaluation of hand grip and lid lag, as well as eye closure and percussion myotonia over the thenar eminence. To detect the presence of myotonic discharges, seen in SCM and PMC, as well as sometimes in HyperPP, a standardized EMG was performed by an experienced neurophysiologist in all patients. This electrophysiological test was carried out at room temperature in a proximal and distal muscle of the upper and lower limb and after cooling of the hand muscle to 22°C. 18 The prolonged exercise test 11 was only proposed in patients with a history of episodic muscle weakness, with the aim to confirm the phenotype of HyperPP or HypoPP.
Only in the presence of clinical and/or electrophysiological features suggesting a muscular sodium channelopathy, genetic testing of the SCN4A gene was performed (Figure 2 ). Analysis for detection of SCN4A mutations was carried out by PCR amplification and Sanger sequencing of all 24 exons and parts (30 bp) of the flanking introns of the SCN4A gene (NM_000334.4 and NG_011699.1). In the absence of SCN4A variants that may affect function in patients with myotonic features, the CLCN1 (chloride channel, voltage sensitive 1, NM_000083.2 and NG_009815.1), which is the other gene involved in nondystrophic myotonia (NDM) was explored (Figure 2 ). 27 CLCN1 was sequenced by PCR amplification and Sanger sequencing of all 23 exons and parts of the flanking introns. As NDM are considered to be highly penetrant genetic disorders, SCN4A or CLCN1 mutations are neither expected nor tested in the absence of clinical and/or electrophysiological features. 27 One family was indicative for DMPK testing (Figure 2) . Detection of the CTG repeat expansion in the 3′-UTR of the DMPK gene was performed with PCR techniques described by Brook et al. 28 and with triplet repeat primed PCR techniques described by Warner et al. 29 adapted for use on the ABI3130 genetic analyzer.
RESULTS
Screening for BS in patients with muscular sodium channelopathies
In the index family (family A in Table 1 ), the three cardiac asymptomatic daughters (A2-A4) all carried the SCN5A polymorphisms c.1673A4G (p.H558R) and c.1141 − 3C4A. Daughters A2 and A3 had a positive Ajmaline Challenge Test, revealing BS (Table 1 and Figure 1 ). During a subsequent electrophysiological study (EPS), no sustained ventricular arrhythmia could be induced in both patients. Therefore, ICD implantation was not indicated and follow-up once a year was proposed. One of both cardiac-affected daughters (A3) carried the same SCN4A variant and the matching neurological phenotype as the father. The youngest daughter (A4) had normal cardiac tests and did not carry this SCN4A variant. One out of 11 patients of 6 additional families, all carrying an SCN4A variant, had a positive Ajmaline Challenge Test (Figure 1 ). No cardiac symptoms or suspicious family history was reported for this patient (G1). The subsequent EPS and SCN5A analyses of this patient were normal and no ICD implantation was proposed at that time.
One cardiac asymptomatic patient (B2) had a baseline Brugada type 2 pattern, which remained unchanged after the challenge test with ajmaline. This ECG pattern is therefore considered to be a normal SCN4A variants and Brugada syndrome V Bissay et al variant rather than a specific predictor of life-threatening arrhythmia. 30 Extensive cardiac work-up in four patients (B3, B4, C2 and D1) with palpitations, syncope or dizziness only demonstrated the occurrence of a non-sustained ventricular tachycardia in one patient with syncope (D1; Table 1 ). Ajmaline testing and SCN5A analysis demonstrated no underlying cardiac channelopathy. All other patients had normal cardiac findings.
Screening for muscular sodium channelopathies in patients with BS Periodic paralysis was not diagnosed in any Brugada patient. Ten Brugada patients from four families had electrophysiological myotonic features (Table 2 ). In one family, a known SCN5A variant was identified and a second family carries a novel SCN5A variant. Both variants were predicted to affect function. 2, 31, 32 In the other two families, no BS-associated variants were identified in SCN5A (H1) and the BS gene panel of 16 additional genes (I1). Clinical, neurophysiological features and genetic diagnoses are described in detail in Table 2 . There was an important intra-and interfamilial variation in severity and distribution of myotonic features (Table 2 and Figure 3 ). Four out of ten patients (H1, I1, I3 and K1) had typical symptoms of myotonia and one (K1) had objective myotonic signs during physical examination. None of them had consulted a physician for these complaints in the past, suggesting a relatively mild impact on their quality of life.
In the proband of the first SCN5A-negative Brugada family (H1), a c.2341G4A p.(Val781Ile) in exon 4 of SCN4A was detected. This variant, currently classified as having no functional effect (Hofman classification; Table 2 ), was previously reported in association with hyperkalemic and normokalemic periodic paralysis. 33, 34 However, a functional expression study supported the hypothesis that this variant should be classified as a rare benign polymorphism rather than a causative mutation. 35 No other family members were included in that study to evaluate segregation. The CLCN1 gene analysis was not performed because no patient consent was obtained. Therefore, we cannot confirm the involvement of SCN4A p.(Val781Ile) in the muscular phenotype of this patient.
Two of the three family members (I1 and I3) of the second SCN5A-negative family (I) had myotonic discharges on EMG and a novel c.3901_3903delCAG (p.(Gln1301del)) variant in the intracellular domain 3-4 of SCN4A. The localization of this amino-acid deletion as well as the phenotype/genotype concordance in the family members advocates the probable function affecting the role of this genetic change.
In the third Brugada family (J), positive for the known SCN5A variant c.2632C4T p.(Arg878Cys), 32 no SCN4A mutation was found in the index patient (J1) who presented myotonic features on EMG. Consequently, the CLCN1 gene was analyzed. All the family members with myotonic features on EMG (J1, J2, J7, J8 and J12) are heterozygous carriers of a c.774+1G4A variant in intron 6, which has not been described before. In this large family, there was a 100% genotype-phenotype concordance for myotonia as none of the myotonia-negative members who were tested (J3, J4 and J9-J11) carried the CLCN1 variant, therefore confirming the causative role for this variant. Based on these findings, we can conclude that some family members, besides having a BS, suffer from (Table 2) , do not display malignant cardiac events (J2 and J8), but have a positive Ajmaline Challenge Test in addition to their myotonic features. The fourth family (K1 and K2) had typical clinical features of a myotonic dystrophy (DM1), including ptosis and atrophy of the temporal and sternocleidomastoid muscle. Discrete distal muscular weakness and percussion myotonia were only observed in the oldest patient (K1). His major complaints were cramps in both hands and grip myotonia, exacerbated by cold. The analysis of the DMPK gene (dystrophia myotonica protein kinase) showed an expansion of the CTG trinucleotide repeat in the 3′ end of the gene in both father (1700 bp) and daughter (900 bp), the presence of which confirmed the diagnosis of DM1 in both patients. In the cardiac symptomatic proband (K1), additional SCN5A gene analysis revealed a novel variant c.5189C4A (p.(Pro1730His)), which probably affects the function. His cardiac asymptomatic daughter (K2) did not carry this variant despite a positive Ajmaline Challenge Test. This finding demonstrates that in this family this SCN5A variant is not disease causing, as it not segregating correctly.
DISCUSSION
We report on three families (families A, G and I) with an SCN4A-related NDM and one family (H) with a possible SCN4A-related NDM in association with BS. Two out of five patients with predicted gain-offunction SCN4A variants, and BS, had cardiac malignant events (A1 and I1). Furthermore, some family members of two other SCN4A-positive families (B and D) displayed cardiac arrhythmia symptoms. One had palpitations and a short documented episode of atrial fibrillation (B3). The second had syncopes and a documented non-sustained ventricular tachycardia (D1). No function affecting SCN5A variant was found in their families. Although two case studies 5, 6 suggested a possible role of SCN4A in cardiac arrhythmogenesis, this association has not yet been documented.
Because SCN4A and SCN5A are not genetically linked to each other (chromosome 17q23 and 3q12, respectively), 36 we need to take a closer look at the role and the localization of Nav1.4 channels in the human cardiac muscle to find a possible explanation for these findings. Distribution of voltage-gated sodium channels differs between different mammalian species. Although ischemic rat hearts SCN4A variants and Brugada syndrome V Bissay et al do not express functional NaV1.4 channels, 37 they are present in mouse, pig and human cardiac tissue. 7 By staining the α-subunit in human atrial tissue, Kaufmann and et al. 8 demonstrated that the tetrodotoxin (TTX)-sensitive Nav1.4 and the non-TTX-sensitive Nav1.5 channels accounted for 2.6% and 87.7% of total sodium channel staining, respectively. The human ventricle also expresses the SCN4A α-subunit gene, 5 and in whole human heart samples, the transcript level of Nav1.4 was 1.1%. 7 Unlike other α channels, both Nav1.4 and Nav1.5 are present in a striated pattern on the cell myocyte surface, in register with the z-lines. 8 How Nav1.5 and Nav1.4 interact with each other is not clear, but their colocalization, which is also similar to the localization of Cav1.2 calcium channels in atrial tissue, could ensure rapid activation of the calcium channels and thus contraction. Whether SCN4A mutations, resulting in dysfunctional Nav1.4 channels, could influence this interchannel interaction and result in a reduced net depolarization current, as seen in BS 38, 39 and/or aberrant calcium channel activation, needs further investigation including functional expression studies and wedge preparation models.
However, we should also emphasize that in contrast to the lossof-function of NaV1.5 sodium channels in the SCN5A-associated BS, muscular sodium channelopathies with myotonic features typically result from a gain-of-function of Nav1.4 channels. Therefore, gain-offunction SCN4A mutations in cardiac tissue are less likely to result in a reduced net depolarization current, as seen in BS. In patients with PMC, prolonged QTc intervals were observed in association with a gain-of-function SCN4A mutation (p.(Arg1448Cys)) 5 . Such repolarization abnormalities have also been seen in long QT syndrome type 3 (LQTS3) as a result of gain-of-function SCN5A mutations. 40 We were, however, unable to demonstrate prolonged QTc intervals in association with p. . In LQTS3, prolongation of the QT interval is expected to result from decreased K + repolarization currents, increased Ca 2+ entry or a sustained entry of Na + (late I Na ) into the cardiomyocyte. 40 Whether a parallelism can be drawn for SCN4A and if SCN4A mutations might result in overlapping clinical properties of different syndromes such as BS and LQTS3 41 requires further investigation.
Our data support the utility of a cardiac work-up in patients with SCN4A mutation or variants. Class Ic antiarrhythmic drugs such as flecainide and propafenone, which are used for the symptomatic treatment of myotonia, are contraindicated in Brugada syndrome. 42, 43 Caution during a challenge test is therefore required. In contrast, Mexiletine, a class Ib antiarrhythmic, is considered to be safe in reducing myotonia 44 and is known to restore trafficking defects in BS. 45, 46 More intriguing is the presence of a rare pathology such as Thomsen disease (o1/100 000) in one BS family (J). It is caused by an CLCN1 variant encoding for the ClC-1 voltage-gated chloride channel. 4 Several chloride channels in the heart, including ClC-2 and ClC-3 voltage-gated chloride channels, have been previously reported as contributors to arrhythmogenesis. 47 Only recently, the expression of CLCN1 mRNA transcripts has been reported in the human brain and heart. 48 Therefore, no clear explanation can be found for the concomitant occurrence of both diseases.
DM1 was diagnosed in one family (K). In recent publications, 49 ,50 a significantly high frequency of spontaneous and ajmaline-induced type 1 Brugada ECG pattern was detected in DM1 patients (prevalence: 0.5-3%), suggesting that our findings are not a coincidence. Patient K1 presented with a VF episode during a febrile episode, a typical phenomenon seen in BS. A possible explanation underlying the link between DM1 and BS could be that the CTG repeats in DMPK result in the accumulation of nuclear mRNA sequences, facilitating abnormal splicing of several genes such as SCN5A. 49 Others suggest that because both DM1 and BS are associated with focal fibrosis and fatty infiltration, 51, 52 their coexistence could amplify the subsequent arising conduction delay in the right ventricle (RV). Such RV delay has been thought responsible for the arrhythmogenesis in BS. 39 The 'pure' self-sufficient causative role of loss-of-function mutations of the SCN5A gene in the Brugada ECG pattern or syndrome has been challenged and BS is no longer thought to be a pure monogenic disorder. Phenotype-positive genotype-negative family members (genotype-phenotype discordance), SCN5A mutation carriers without a spontaneous or induced type 1 BS ECG pattern (incomplete penetrance) and family members who carry the same SCN5A mutation and express wide-ranging clinical manifestations (variable expression) support this statement. 53 Only about 35% of BS patients have been determined to have a genetic cause and nearly 30% carry a mutation in SCN5A. Besides the known mutations in several genes (SCN5A, GPD1L, SCN1B, SCN2B, SCN3B, MOG1, RANGRF, SLMAP, KCNE3, KCNJ8, HCN4, KCNE5, KCND3, CACNA1C, CACNB2, CACNA2D1, SCN10A and TRPM4), 2,3 other factors also have an important role in the resulting phenotype such as additional variants 54 (compound heterozygous disease-associated polymorphisms in family A), 15, 16, 55 epigenetic mechanisms (DNA methylation, posttranslational modifications and RNA mechanisms) 56 and phenotype modulators (vagal tone, sex hormones and febrile status). 57 It is likely that these additional factors influence the precise phenotypic expression and are therefore responsible for phenotypic overlap 41 and variable expressivity or incomplete penetrance 58 as seen in these families. As described for SCN10A, which encodes the sodium channel isoform Nav1.8, 54 the presence of an SCN4A variant or a CLCN1 variant or the expansion of a CTG trinucleotide repeat in DMPK, is probably not solely responsible for an arrhythmic event, but would rather act as an additional modifier. Further studies, including genome-wide association studies, are required to further assess the influence of these additional variants on conduction and BS.
In conclusion, we report a high number of patients with coexisting BS and SCM. Our findings suggest a possible impact of SCN4A variants on the pathophysiological mechanism underlying the development of a type 1 ECG pattern and of malignant arrhythmia symptoms in some patients with BS.
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